Phagenesis raised €39M in a Series D+ round in Mar 2024. The company is based in Manchester Science Park Pencroft, UK. Investors in the round: Aphelion, British Patient Capital, EQT Life Sciences and 2 others. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
